Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Hospital Center, Périgueux rodon.philippe@wanadoo.fr.
Philippe
P
Rodon
University Hospital, Nancy.
Cyrille
C
Hulin
University Hospital, Grenoble, France.
Brigitte
B
Pegourie
Hospital Center, La Roche sur Yon, France.
Mourad
M
Tiab
Hospital Center, Valence.
Bruno
B
Anglaret
University Hospital, Tours.
Lotfi
L
Benboubker
Hospital Center, Vannes.
Henry
H
Jardel
University Hospital, Rennes.
Olivier
O
Decaux
University Hospital, Reims.
Brigitte
B
Kolb
University Hospital, Toulouse.
Murielle
M
Roussel
Hôpital St Antoine, Assistance Publique-Hôpitaux de Paris, Paris.
Laurent
L
Garderet
University Hospital, Lille.
Xavier
X
Leleu
Polyclinique Nord-Aquitaine, Bordeaux.
Olivier
O
Fitoussi
University Hospital, Clermont-Ferrand.
Carine
C
Chaleteix
Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny.
Philippe
P
Casassus
Centre de Lutte contre le Cancer Rouen, France.
Pascal
P
Lenain
University Hospital, Amiens.
Bruno
B
Royer
Hospital Center, Bayonne.
Anne
A
Banos
Hospital Center, Pontoise.
Riad
R
Benramdane
Hospital Center, Annecy.
Pascale
P
Cony-Makhoul
University Hospital, Angers.
Mamoun
M
Dib
University Hospital, Besançon.
Jean
J
Fontan
Institut Paoli Calmette, Marseille.
Anne-Marie
AM
Stoppa
University Hospital, Lyon.
Catherine
C
Traullé
Centre François Baclesse, Caen.
Jean-Pierre
JP
Vilque
University Hospital, Lille.
Marie-Odile
MO
Pétillon
Institut Curie, Paris.
Claire
C
Mathiot
University Hospital, Nantes, France.
Thomas
T
Dejoie
University Hospital, Toulouse.
Hervé
H
Avet-Loiseau
University Hospital, Nantes, France.
Philippe
P
Moreau
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage; D015996:Survival Rate
D001897:Boronic Acids; D009588:Nitrogen Mustard Compounds; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D000069461:Bendamustine Hydrochloride
bendamustine; elderly; multiple myeloma; relapse